Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage - PubMed (original) (raw)
. 2001 Jan 12;276(2):1391-7.
doi: 10.1074/jbc.M004113200.
Affiliations
- PMID: 11027678
- DOI: 10.1074/jbc.M004113200
Free article
Mode of action of an antiviral peptide from HIV-1. Inhibition at a post-lipid mixing stage
Y Kliger et al. J Biol Chem. 2001.
Free article
Abstract
DP178, a synthetic peptide corresponding to a segment of the transmembrane envelope glycoprotein (gp41) of human immunodeficiency virus, type 1 (HIV-1), is a potent inhibitor of viral infection and virus-mediated cell-cell fusion. Nevertheless, DP178 does not contain gp41 coiled-coil cavity binding residues postulated to be essential for inhibiting HIV-1 entry. We find that DP178 inhibits phospholipid redistribution mediated by the HIV-1 envelope glycoprotein at a concentration 8 times greater than that of solute redistribution (the IC(50) values are 43 and 335 nm, respectively). In contrast, C34, a synthetic peptide which overlaps with DP178 but contains the cavity binding residues, did not show this phenomenon (11 and 25 nm, respectively). The ability of DP178 to inhibit membrane fusion at a post-lipid mixing stage correlates with its ability to bind and oligomerize on the surface of membranes. Furthermore, our results are consistent with a model in which DP178 inhibits the formation of gp41 viral hairpin structure at low affinity, whereas C34 inhibits its formation at high affinity: the failure to form the viral hairpin prevents both lipid and solute from redistributing between cells. However, our data also suggest an additional membrane-bound inhibitory site for DP178 in the ectodomain of gp41 within a region immediately adjacent to the membrane-spanning domain. By binding to this higher affinity site, DP178 inhibits the recruitment of several gp41-membrane complexes, thus inhibiting fusion pore formation.
Similar articles
- The possible involvement of CXCR4 in the inhibition of HIV-1 infection mediated by DP178/gp41.
Xu Y, Zhang X, Matsuoka M, Hattori T. Xu Y, et al. FEBS Lett. 2000 Dec 29;487(2):185-8. doi: 10.1016/s0014-5793(00)02336-x. FEBS Lett. 2000. PMID: 11150506 - Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41.
Muñoz-Barroso I, Durell S, Sakaguchi K, Appella E, Blumenthal R. Muñoz-Barroso I, et al. J Cell Biol. 1998 Jan 26;140(2):315-23. doi: 10.1083/jcb.140.2.315. J Cell Biol. 1998. PMID: 9442107 Free PMC article. - Inhibition of HIV-1 entry before gp41 folds into its fusion-active conformation.
Kliger Y, Shai Y. Kliger Y, et al. J Mol Biol. 2000 Jan 14;295(2):163-8. doi: 10.1006/jmbi.1999.3368. J Mol Biol. 2000. PMID: 10623516 - Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.
Cai L, Gochin M, Liu K. Cai L, et al. Curr Top Med Chem. 2011 Dec;11(24):2959-84. doi: 10.2174/156802611798808497. Curr Top Med Chem. 2011. PMID: 22044229 Free PMC article. Review. - Multifaceted action of Fuzeon as virus-cell membrane fusion inhibitor.
Ashkenazi A, Wexler-Cohen Y, Shai Y. Ashkenazi A, et al. Biochim Biophys Acta. 2011 Oct;1808(10):2352-8. doi: 10.1016/j.bbamem.2011.06.020. Epub 2011 Jul 5. Biochim Biophys Acta. 2011. PMID: 21762676 Review.
Cited by
- Crystal structure of HIV-1 gp41 including both fusion peptide and membrane proximal external regions.
Buzon V, Natrajan G, Schibli D, Campelo F, Kozlov MM, Weissenhorn W. Buzon V, et al. PLoS Pathog. 2010 May 6;6(5):e1000880. doi: 10.1371/journal.ppat.1000880. PLoS Pathog. 2010. PMID: 20463810 Free PMC article. - Pharmacologic and nonpharmacologic options for the management of HIV infection during pregnancy.
Zorrilla CD, Tamayo-Agrait V. Zorrilla CD, et al. HIV AIDS (Auckl). 2009;1:41-53. doi: 10.2147/hiv.s6326. Epub 2009 Dec 8. HIV AIDS (Auckl). 2009. PMID: 22096378 Free PMC article. - Enfuvirtide (T20)-Based Lipopeptide Is a Potent HIV-1 Cell Fusion Inhibitor: Implications for Viral Entry and Inhibition.
Ding X, Zhang X, Chong H, Zhu Y, Wei H, Wu X, He J, Wang X, He Y. Ding X, et al. J Virol. 2017 Aug 24;91(18):e00831-17. doi: 10.1128/JVI.00831-17. Print 2017 Sep 15. J Virol. 2017. PMID: 28659478 Free PMC article. - Prediction of viral oncoproteins through the combination of generative adversarial networks and machine learning techniques.
Beltrán JF, Herrera-Belén L, Yáñez AJ, Jimenez L. Beltrán JF, et al. Sci Rep. 2024 Nov 7;14(1):27108. doi: 10.1038/s41598-024-77028-y. Sci Rep. 2024. PMID: 39511292 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical